At least 100 cases reached more than the upper level life expectancy; forty-seven continue to be approaching but many of these are without a contact in quite a long time. Seventy-four have been discovered to have passed away. Many cases remain without complete data for complete analysis. At least 67% or two-thirds of the patients whom I have found providing data on the web have exceeded the upper level life expectancy where only about 20% were expected to do so . . . thus much bias must be found in order to challenge the efficacy 'claim' this set is representing. The more recent cases seem to be doing better . . . possibly because patients obtain their implant nearer the optimal point in the disease's course. We should remind ourselves the symptoms may belong to more than one actual disease and plausibly the pacer doesn't help with every one of them. Further research is needed to find 'fault-lines' to help us ascertain the basis for benefit and, if there are case types the treatment will not benefit then how to detect them, especially if there are cases where the treatment might cause harm.